Mirati Therapeutics Inc (MRTX) Major Shareholder Boxer Capital, Llc Sells 550,000 Shares

Mirati Therapeutics Inc (NASDAQ:MRTX) major shareholder Boxer Capital, Llc sold 550,000 shares of the business’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $52.10, for a total transaction of $28,655,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

NASDAQ MRTX opened at $53.67 on Thursday. Mirati Therapeutics Inc has a 52 week low of $18.00 and a 52 week high of $65.35. The firm has a market cap of $1.46 billion, a PE ratio of -19.31 and a beta of 1.49.

Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.02. Research analysts anticipate that Mirati Therapeutics Inc will post -3.12 EPS for the current year.

A number of research firms have recently commented on MRTX. BidaskClub raised shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 5th. Zacks Investment Research raised shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $50.00 target price on the stock in a research report on Friday, January 4th. B. Riley began coverage on shares of Mirati Therapeutics in a research report on Friday, November 30th. They set a “buy” rating and a $60.00 target price on the stock. Jefferies Financial Group reissued a “hold” rating and set a $37.00 target price on shares of Mirati Therapeutics in a research report on Thursday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Mirati Therapeutics in a research report on Monday, November 12th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Mirati Therapeutics currently has a consensus rating of “Buy” and an average target price of $54.89.

Large investors have recently modified their holdings of the stock. Legal & General Group Plc bought a new stake in shares of Mirati Therapeutics in the second quarter worth $150,000. Pacer Advisors Inc. bought a new stake in shares of Mirati Therapeutics in the third quarter worth $176,000. Renaissance Technologies LLC bought a new stake in shares of Mirati Therapeutics in the second quarter worth $227,000. GAM Holding AG bought a new stake in shares of Mirati Therapeutics in the third quarter worth $236,000. Finally, United Services Automobile Association bought a new stake in shares of Mirati Therapeutics in the second quarter worth $250,000.

COPYRIGHT VIOLATION WARNING: “Mirati Therapeutics Inc (MRTX) Major Shareholder Boxer Capital, Llc Sells 550,000 Shares” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2019/01/10/mirati-therapeutics-inc-mrtx-major-shareholder-boxer-capital-llc-sells-550000-shares.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.

Further Reading: Price to Earnings Ratio (PE) Basics

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply